With a tinge of both nostalgia and anticipation, I am pleased to announce a number of management changes at the Bureau. As you may have heard, Deputy Director Steve Weissman will be returning to private practice shortly. Steve is heading back to Baker Botts, where he will help lead the firm’s antitrust group. Steve has been a terrific deputy with numerous accomplishments, including leading the FTC team to victory in FTC v. Sysco/US Foods. He also handled a number of complicated investigations to a successful conclusion, such as our recent monopolization order against Cardinal Health, which included disgorgement of $26.8 million in ill-gotten gains, and helping prepare the Commission’s challenge to Verisk Analytic’s proposed acquisition of EagleView Technology, which the parties abandoned prior to litigation.
Stepping up to take over the duties as Acting Deputy Director is Markus H. Meier, Assistant Director of our Health Care Division. Markus is a veteran of the FTC (and the U.S. Army), who has been leading one of the Commission’s most important competition enforcement initiatives—subjecting anticompetitive pharmaceutical reverse payment settlements to antitrust scrutiny. Markus is simply a great antitrust attorney and a consummate manager. I am grateful that he has agreed to help me lead the Bureau of Competition and manage its workload, while continuing to play a substantial role in the agency’s health care matters.
Another stalwart BC manager, Phill Broyles, Assistant Director of Mergers III, has decided to take a well-deserved retirement at the end of this year. Phill has made enormous contributions as the AD of M3 for nearly 20 years, and the Regional Director in the Commission’s Cleveland office for four years before that. Phill has been at the helm for a spate of large oil mergers and the Commission’s successful litigation to block Staples’ acquisition of Office Depot. We will miss Phill greatly and have posted an opening for a new AD in Mergers III.
Chuck Loughlin joined the Bureau in September, as the Deputy Assistant Director of the litigation shop that Tara Reinhart heads. He brings with him 20 years of experience in antitrust litigation, first at Howrey LLP and then at Baker Botts, where he was a partner in the antitrust group. Chuck litigated cases in a number of industries, including pharmaceuticals, financial services, grocery distribution, high-tech, automobiles, and construction equipment. He has been involved in antitrust investigations before the DOJ and FTC, so he is a familiar face here at the Bureau. Chuck is a graduate of the University of New Hampshire and Georgetown University Law Center.
Finally, Dominic Vote will be the new Deputy Assistant Director of Mergers II, filling out the M2 management team that includes AD Ben Gris and DAD James Rhilinger. A graduate of American University’s Washington College of Law, Dom joined BC’s Health Care Division in 2010, after working in private practice and clerking for a federal district judge. Dom has investigated and litigated several pharmaceutical conduct cases and played a key role in the Commission’s reverse payment case against Cephalon, which resulted in the largest monetary award ever obtained by the Commission. Dom has most recently been a Counsel to the Director, handling a variety of merger matters being investigated by the Mergers I, Mergers III, and Northwest Regional Divisions.